EMA Recommends to Extend Therapeutic Indications for Crizotinib in Paediatric Patients
Extension to already existing indications in ALK-positive anaplastic large cell lymphoma and unresectable inflammatory myofibroblastic tumour concerns the treatment of children from 1 year of age